The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2020

Filed:

Aug. 28, 2017
Applicant:

Hackensack University Medical Center, Hackensack, NJ (US);

Inventor:

Yong Zhao, River Edge, NJ (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/51 (2015.01); A61K 38/18 (2006.01); A61K 38/30 (2006.01); C12N 5/00 (2006.01); A61L 27/36 (2006.01); C12N 5/071 (2010.01); A61K 38/28 (2006.01); A61K 35/17 (2015.01); A61K 35/39 (2015.01); G01N 30/88 (2006.01);
U.S. Cl.
CPC ...
A61K 35/51 (2013.01); A61K 35/17 (2013.01); A61K 35/39 (2013.01); A61K 38/18 (2013.01); A61K 38/28 (2013.01); A61K 38/30 (2013.01); A61L 27/3616 (2013.01); C12N 5/0018 (2013.01); C12N 5/0676 (2013.01); C12N 2500/84 (2013.01); C12N 2502/115 (2013.01); C12N 2506/115 (2013.01); C12N 2513/00 (2013.01); G01N 2030/8813 (2013.01); G01N 2333/59 (2013.01);
Abstract

The described invention provides a method of functionally reprogramming adult cells to an immature cell type that expresses one or more embryonic biomarkers. The reprogramming is accomplished by contacting the adult cells with a platelet rich fraction comprising platelet-like cells from umbilical cord blood or peripheral blood, and expanding the immature cell type in vitro under culture conditions to generate an insulin-producing cell population that expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells. Without being limited by theory, platelet-like cells and their released mitochondria display immune tolerance-associated markers that may modulate the function and differentiation of immune cells. The described invention further provides a pharmaceutical composition comprising a cell product containing a therapeutic amount of an insulin-producing cell population derived from functionally reprogrammed adult cells, wherein the insulin-producing cell population expresses human beta-cell specific transcription factors and is functionally equivalent to human pancreatic beta-cells.


Find Patent Forward Citations

Loading…